Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
13,059 total articles
Clearmind Medicine Inc., a clinical-stage biotech focused on non-hallucinogenic neuroplastogen therapies, announced it is evaluating its lead candidate CMND-100 (MEAI) for eligibility for the FDA's Breakthrough Therapy Designation based on positive Phase I/IIa clinical trial results in Alcohol Use Disorder. The designation could accelerate developm…
CADV Ventures S.A., a Poland-based AI software company specializing in AI-assisted IT support services, has entered into a business combination agreement with Miluna Acquisition Corp, a US-based SPAC listed on Nasdaq. Upon closing, the combined company will be named Kukugan Corp and listed on a national securities exchange, with an implied enterpri…
CorMedix Therapeutics reported positive topline results from the Phase III ReSPECT trial evaluating REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in adults undergoing allogeneic hematopoietic stem cell transplantation. The study met its primary endpoint, demonstrating non-inferiority to standard antimicrobial regimens for fu…
Greenlane Holdings, Inc., a Nasdaq-listed digital asset treasury company focused on the Berachain ecosystem, announced that it has regained compliance with Nasdaq's minimum bid price requirement and will continue its listing on the Nasdaq Capital Market under the ticker GNLN. The company's leadership expressed confidence in its Berachain-focused di…
Kustom Entertainment announces its CEO Stanton E. Ross will present at the 16th Annual LD Micro Invitational to outline the company's strategic progress, including its rebrand, business divestitures, expansion of live events, and positive 2026 outlook. The company emphasizes its shift towards a focused live entertainment and ticketing business mode…
NervGen Pharma Corp., a clinical-stage biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury, announced the appointment of Keith Vendola as Chief Financial Officer. Vendola brings over 20 years of financial and strategic leadership experience in biopharma and healthcare investment banking. His expertise is expecte…
WW International, Inc., known as Weight Watchers, announced its intention to utilize up to $40 million in cash to prepay and reduce the principal amount of its outstanding term loan. This action includes paying the annual cash sweep amount due in June 2026 and a voluntary prepayment solicitation to reduce debt at a discount. The company reaffirmed …
HCW Biologics announced preclinical data showing its lead T-Cell Engager candidate, HCW11-018b, penetrates the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities. The data, presented at AACR 2026, revealed the drug's mechanism of action based on cis-binding, which enhances efficacy and tolerability. The compan…
Compass Therapeutics announced that tovecimig, a bispecific antibody targeting DLL4 and VEGF-A, combined with paclitaxel, significantly improved median progression-free survival (PFS) and overall response rate (ORR) in patients with unresectable advanced biliary tract cancer in the Phase 2/3 COMPANION-002 study. The treatment reduced risk of progre…
Medicus Pharma's CEO and leadership team met with key U.S. healthcare policymakers on the House Energy & Commerce Committee to promote orphan drug designation and investigational new drug approval for SkinJect®, a novel treatment for Gorlin Syndrome. The company emphasizes SkinJect®'s potential to provide a non-surgical, repeatable therapy for a ra…
BriaCell Therapeutics Corp. announced six clinical data presentations at the 2026 ASCO Annual Meeting, featuring key findings from their Phase 2 and ongoing Phase 3 trials of their novel immunotherapy Bria-IMT combined with CPI in advanced metastatic breast cancer. The presentations include survival data, quality of life assessments, and biomarker …
Keel Infrastructure Corp., a North American digital and energy infrastructure company, will report its first quarter 2026 financial results on May 11, 2026, before the market opens. Management will host a conference call the same day to discuss the results.
Scorpio Tankers Inc. announced a $50 million credit facility commitment from Bank of America to finance two 2015-built LR2 product tankers. The facility has a seven-year maturity and competitive interest terms. This financial move supports Scorpio Tankers' fleet expansion and modernization amid ongoing vessel sales and newbuilding deliveries.
Alterity Therapeutics announced positive regulatory feedback from the FDA following their second Type C Meeting concerning the chemistry, manufacturing, and control aspects of their planned Phase 3 trial for ATH434 in Multiple System Atrophy (MSA). This progress marks a crucial step toward initiating the pivotal trial, with concurrent manufacturing…
Sagimet Biosciences has priced an underwritten offering of 29.17 million Series A common stock shares at $6.00 each, aiming to raise approximately $175 million. The proceeds will fund late-stage clinical trials including a Phase 3 study for denifanstat in moderate to severe acne, advance pipeline candidates through Phase 2 results, and support gene…
Allot Ltd., a global provider of Security-as-a-Service and network intelligence solutions, announced it will release its first quarter 2026 financial results and hold a conference call on May 12, 2026. The company provides cybersecurity and network analytics solutions to service providers and enterprises worldwide.
HBT Financial, Inc. announced first quarter 2026 results with net income of $11.2 million ($0.34 per diluted share) and adjusted net income of $22.6 million ($0.68 per diluted share). The company completed its merger with CNB Bank Shares, Inc. on March 1, 2026, successfully integrating systems. Asset quality remained strong with low nonperforming a…
Youxin Technology Ltd announced it will acquire an 18% equity stake in YATOP Group Limited, a leading TikTok marketing and branding agency, for approximately $10.8 million via share exchange. This strategic investment aims to enhance Youxin's SaaS and PaaS digital commerce ecosystem by integrating YATOP's strong global influencer marketing and e-co…
Purple Biotech announced new preclinical data validating the efficacy of IM1240, its lead CAPTN-3 tri-specific antibody. Generated by Dr. Amir Horowitz's team at Mount Sinai, the data shows IM1240's NKG2A arm significantly enhances anti-tumor activity across multiple resistant patient-derived tumor samples, including PD-1 resistant cancers. The ant…
Ligand Pharmaceuticals announced the acquisition of XOMA Royalty Corporation for approximately $739 million in cash, adding over 120 assets including seven marketed products and significantly expanding its royalty portfolio across multiple therapeutic areas. The acquisition is expected to be immediately accretive to adjusted EPS and has prompted Li…
Aurora Mobile's sub-brand MoonFox Data showcased its sophisticated multi-dimensional alternative data platform at the Neudata Hong Kong Summit, demonstrating how its online, offline, transactional, and sentiment data enable investors to forecast earnings and generate alpha in Chinese markets. MoonFox highlighted its extensive coverage of over 600 l…
Seer, Inc.'s Board of Directors unanimously rejected a revised unsolicited acquisition proposal from the Radoff-JEC Group offering $2.35 per share plus contingent value rights. The Board stated the offer significantly undervalues Seer considering its strong growth potential, proprietary proteomics platform, increasing adoption, and large market opp…
Sagimet Biosciences announced plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. starting in the second half of 2026, following positive Phase 3 results reported in China. The company is also advancing its FASN inhibitor pipeline with an ongoing Phase 1 trial of TVB-3567 and is prioritizing dermatology…
Ocular Therapeutix, a biopharmaceutical company focused on retinal disease treatments, has announced its participation in various upcoming scientific and investor conferences in May 2026. The company will present clinical trial results, particularly for its investigational product AXPAXLI (OTX-TKI), currently in Phase 3 trials for wet age-related m…
Intellia Therapeutics has started a rolling submission of a biologics license application to the FDA seeking approval for lonvoguran ziclumeran (lonvo-z), an innovative one-time in vivo CRISPR gene-editing treatment for hereditary angioedema (HAE). Positive topline Phase 3 HAELO trial data indicate that lonvo-z met primary and secondary endpoints, …
